AI-enhanced levodopa challenge test for parkinsonism
Part of Brain & nervous system, Eyes & vision clinical trials.
This study uses artificial intelligence (AI) to improve a standard test for parkinsonism called the levodopa challenge test. It may help doctors better understand how your movement symptoms respond to levodopa, a common Parkinson's medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old.
- You have been diagnosed with one of the following: Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, vascular parkinsonism, drug-induced parkinsonism, corticobasal degeneration, or dementia with Lewy bodies.
- You can safely take a levodopa challenge test (a short test where you take a dose of levodopa and your symptoms are watched).
- You do not have major memory or thinking problems that would prevent you from understanding the study.
- You do not have a serious heart, lung, liver, or kidney condition, or an unstable cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence to analyze facial expressions and speech patterns in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. The goal is to find digital markers that may help track the disease.
This study follows people with certain rare brain conditions that affect movement and thinking, such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration. It aims to learn more about how these conditions progress over time, which may help improve future care.
This trial tests a new non-invasive brain stimulation method guided by MRI to see if it can improve Parkinson's symptoms. It may be an option for people who respond well to their current Parkinson's medications.
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
Hear when a new Vascular Parkinsonism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.